
Eye Allergy Treatment Market
Eye Allergy Treatment Market Research Report Information By Type (Seasonal and Perennial Allergic Conjunctivitis, Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, Contact Allergic Conjunctivitis, Giant Papillary Conjunctivitis), By Drug Class (Antihistamine, Mast Cell Stabilizer, NASAIDs, Corticosteroid, Decongestants, Immunotherapy Allergy Shots, Others), By Treatment Form (Eyedrops, Injectables, Tablets & Capsules), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) And By Region (North Amer...
Eye Allergy Treatment Market Trends
The increasing prevalence of eye allergies across the world is burgeoning the growth of the Eye Allergy Treatment Market. For instance, in February 2020, Alcon, a Novartis AG (US) company, reported that there were nearly 66 million Americans suffering from eye allergies. Moreover, the increasing geriatric population is also fueling the growth of the eye allergy treatment market.
For instance, as per Senior Home Plus (UK), eye allergies in the elderly population occur due to a weakened immune system, chronic health conditions, reduced tear production, and some medication side effects that have been prescribed to the elderly population. market for significant growth. For instance, according to the World Population Prospects 2022, the population over the age of 65 is growing faster than the population under that age. Moreover, it has been estimated that that the proportion of the global population aged 65 and up was expected to rise from 10% in 2022 to 16% by 2050.
Furthermore, the increasing geriatric population in Asia-Pacific will create lucrative growth opportunities in upcoming years. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Thus, the increasing prevalence of eye allergies and the growing geriatric population are burgeoning the growth of the global market.
The eye allergy treatment market is expanding rapidly, fuelled by new drug launches aimed at meeting high demand. With an increasing global prevalence of eye allergies, there is a greater demand for effective and innovative treatment options. For instance, in September 2020, Dr. Reddy's Laboratories (India) launched an over the counter (OTC) eye allergy drop, namely olopatadine hydrochloride ophthalmic solution, in the US market. This solution is indicated for the temporary relief of itchy eyes due to pollen, ragweed, animal hair, dander, and grass.
Furthermore, in February 2020, Alcon (Switzerland) company, launched Pataday, an eye allergy drop that contains olopatadine hydrochloride ophthalmic solution. The Pataday brand features the No. 1 doctor-prescribed eye allergy itch relief ingredient as well as the first once-daily allergy itch relief drop available without a prescription. As a result, the eye allergy treatment market is rapidly expanding, with opportunities for further growth as companies address patients' evolving needs.
Market Segment Insights
Eye Allergy Treatment Type Insight
Based on type, the Eye Allergy Treatment Market has been segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial
allergic conjunctivitissegment dominated the market in 2023, while the atopic keratoconjunctivitis segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.
Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are among the most common forms of eye allergies worldwide. They are triggered by allergens such as pollen, dust mites, and animal dander, affecting a large population during specific seasons or year-round. There are well-established treatment options for Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC), including antihistamine eye drops, mast cell stabilizers, corticosteroids, and combination therapies. These treatments effectively alleviate symptoms and manage allergic reactions, contributing to the segment's market dominance.
Figure 2: EYE ALLERGY TREATMENT MARKET SIZE, BY TYPE, 2023 & 2032 (USD Billion)
Eye Allergy Treatment Drug Class Insights
Based on drug class, the Eye Allergy Treatment Market is segmented into antihistamine, mast cell stabilizer, NSAIDS, corticosteroid, decongestants, immunotherapy allergy shots, and others. The antihistamine segment dominated the market in 2023, while the immunotherapy allergy shots segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.
Antihistaminesare widely recognized for their ability to block histamine receptors, which are responsible for allergic reactions such as itching, redness, and swelling of the eyes. They provide rapid relief from allergy symptoms. Patients often prefer antihistamines due to their established efficacy, rapid onset of action, and minimal systemic side effects compared to other drug classes. Antihistamines have been fundamental in allergy treatment for many years, with extensive clinical research supporting their efficacy and safety. This strong foundation of evidence built a confidence in healthcare providers and patients alike, contributing to their ongoing dominance in eye allergy treatment market.
Eye Allergy Treatment, by Treatment Form Insights
Based on treatment form, the Eye Allergy Treatment Market is segmented into eyedrops, injectables, and tablets & capsules. The eyedrops segment dominated the market in 2023, while the injectables segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.
Eyedrops are specifically formulated for direct application to the eyes, allowing for targeted delivery of medications to relieve symptoms such as itching, redness, and irritation associated with eye allergies. This direct application provides rapid relief and is convenient for patients. They are generally easy to administer and can be used multiple times a day as needed. Patients appreciate the simplicity and non-invasive nature of eyedrop treatments compared to injectables or oral medications. Many eyedrop formulations for mild to moderate eye allergies are available over the counter (OTC), making them easily accessible without requiring a prescription.
This accessibility contributes to their widespread use and market dominance.
Eye Allergy Treatment Distribution Channel Insights
Based on distribution channel, the Eye Allergy Treatment Market is segmented into hospital pharmacies, online pharmacy, and retail pharmacy. The hospital pharmacies segment dominated the market in 2023, while the retail pharmacy segment is projected to be the fastest-growing segment during the forecast period, 2024–2032.
Hospital pharmacies ensure immediate access to a wide range of medications required for treating severe or acute eye allergies. This includes injectables, specialized eye drops, and medications that may not be readily available in retail pharmacies or online. For patients experiencing severe allergic reactions affecting the eyes, hospital pharmacies offer emergency care and critical support. Therefore, Hospital pharmacies play a pivotal role in the eye allergy treatment market due to their capacity to deliver specialized care, prompt access to medications, emergency readiness, strict adherence to regulatory standards, and seamless integration into healthcare systems.
These elements combine to establish their dominance in effectively managing and treating diverse types of eye allergies.
Industry Developments
Santen Pharmaceutical Co., ltd receives U.S. FDA Approval for Verkazia (Cyclosporine ophthalmic emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
May 2021:Teva Pharmaceuticals (Israel) has announced the launch of generic Erythromycin tablets in 250 mg and 500 mg strengths, which are therapeutic equivalents of Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets.
February 2021:Bausch + Lomb (Canada) Launched Alaway Preservative Free Antihistamine Eye Drops. This medication is used to prevent and treat itching of the eyes caused by allergies (allergic/seasonal conjunctivitis)
May 2020: The US Food and Drug Administration (FDA) has approved Alcon's Pataday eye allergy scratch drop. Pataday Ophthalmic Solution belongs to the class of medications called antihistamines. It is used to treat seasonal allergic conjunctivitis, an allergic reaction caused by fur, dust, pollen, and other allergens that cause an eye infection, redness, inflammation, and swelling.
November 2019: Santen Pharmaceutical Co. Ltd (Japan) launched an anti-allergic ophthalmic solution Alesion LX Ophthalmic Solution 0.1% in Japan. This medicine suppresses allergic symptoms such as itchy/bloodshot eyes by histamine H1-receptor antagonism and suppressing the release of allergy-causing substances such as histamine. In most cases, allergic conjunctivitis is treated with it.
October 2019:Sun Pharmaceutical Industries Ltd.'s (India) wholly owned subsidiary has launched CEQUA (cyclosporine ophthalmic solution) 0.09% in the United States. CEQUA, the FDA-approved highest dosage of cyclosporine for ocular usage, can boost tear production in patients with keratoconjunctivitis sicca.
Market Segmentation
Type Outlook
- Seasonal and Perennial Allergic Conjunctivitis
- Vernal Keratoconjunctivitis
- Atopic Keratoconjunctivitis
- Contact Allergic Conjunctivitis
- Giant Papillary Conjunctivitis
Eye Allergy Treatment Form Outlook
- Eyedrops
- Injectables
- Tablets & Capsules
Eye Allergy Treatment Type Outlook
- Seasonal and Perennial Allergic Conjunctivitis
- Vernal Keratoconjunctivitis
- Atopic Keratoconjunctivitis
- Contact Allergic Conjunctivitis
- Giant Papillary Conjunctivitis
Eye Allergy Treatment Regional Outlook
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East
- Africa
- Latin America
Eye Allergy Treatment Drug Class Outlook
- Antihistamine
- Mast Cell Stabilizer
- NASAIDs, Corticosteroid
- Decongestants
- Immunotherapy Allergy Shots
- Others
Eye Allergy Treatment Distribution Channel Outlook
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Report Scope
Attribute/Metric | Details |
Market Size 2024 | USD 3.55 billion |
Market Size 2035 | 6.30 |
Compound Annual Growth Rate (CAGR) | 5.35% (2025 - 2035) |
Base Year | 2024 |
Forecast Period | 2025 - 2035 |
Historical Data | 2019 to 2022 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends. |
Segments Covered | Type, Drug Class, Treatment Form, Distribution Channel, and Region |
Key Companies Profiled | Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries ltd., Teva Pharmaceutical Industries ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., ltd., Alcon, Bayer AG |
Key Market Opportunities | Ongoing clinical trials |
Key Market Dynamics | Rising prevalence of eye allergy and expanding geriatric population. Surging drug launches in order to meet high demand. |
Market Size 2025 | 3.74 |
Market Highlights
FAQs
What is the projected growth of the Eye Allergy Treatment market?
The Eye Allergy Treatment market is the expected increase in total market value of 6.3 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.
What is the size of the Eye Allergy Treatment market?
Eye Allergy Treatment market size was valued at approximately 3.55 billion USD in 2024. This figure will reach 6.3 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.
What is the CAGR of the Eye Allergy Treatment market?
Eye Allergy Treatment market is expected to grow at a CAGR of 5.35% between 2025 and 2035.
How much will the Eye Allergy Treatment market be worth by 2035?
Eye Allergy Treatment market is expected to be worth of 6.3 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.
How will the Eye Allergy Treatment market perform over the next 10 years?
Over the next 10 years the Eye Allergy Treatment market is expected to shift from usd billion 3.55 to 6.3 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.
Kindly complete the form below to receive a free sample of this Report
Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

“Thank you, this will be very helpful for OQS.”

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”